Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04565236
Other study ID # 19855
Secondary ID 2021-003537-11
Status Completed
Phase Phase 4
First received
Last updated
Start date September 22, 2020
Est. completion date March 15, 2024

Study information

Verified date March 2024
Source Bayer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to gather more information on safety and efficacy of Kovaltry for the prevention and treatment of bleeds in Chinese children, adolescents/adults with severe hemophilia A. In addition, pharmacokinetic parameters of Kovaltry will be assessed in a subset of patients.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date March 15, 2024
Est. primary completion date March 15, 2024
Accepts healthy volunteers No
Gender Male
Age group 0 Years to 65 Years
Eligibility Inclusion Criteria: Part A (PTPs): - Chinese participants with severe hemophilia A (defined as Factor VIII (FVIII): C < 1% with one- stage clotting assay documented at the time of screening) - Currently receiving on-demand or any type of prophylaxis treatment regimen with any FVIII product - For participants < 12 years of age, = 50 exposure days (ED); for participants = 12 to 65 years of age, = 150 ED with any FVIII product - No current evidence of inhibitor - No history of FVIII inhibitor formation - Signed informed consent Part B (PUPs/MTPs): - Participants must be <6 years of age at the time of their parent or legal representative's signature of informed consent on the participant's behalf - Chinese participants with severe hemophilia A (defined as Factor VIII (FVIII): C < 1% with one- stage clotting assay documented at the time of screening) - PUPs must have no previous exposure to any FVIII product. MTPs must have no more than 1 ED with any purified FVIII concentrate or 3 exposures with FFP or cryoprecipitate. - MTPs must have no current evidence of inhibitor antibody as measured by the Nijmegen-modified Bethesda assay (<0.6 BU/mL) in 2 consecutive samples and must have absence of clinical signs or symptoms of decreased response to FVIII administration. Testing for the 2 negative samples must be performed by the central laboratory at least 1 week but not more than 2 weeks apart. Participants may not receive FVIII product within 72 hours prior to the collection of samples for inhibitor testing. - PUPs and MTPs must observe a 6-month washout period if they have received subcutaneous factor substitution therapy (emicizumab). - PUPs may be included if they will receive their first FVIII dose with KOVALTRY for treatment of first bleed and agree to start prophylaxis as part of their care. MTPs may be included if they agree to start prophylaxis as part of their care. Exclusion Criteria: Part A (PTPs): - Any other bleeding disease that is different from hemophilia A (e.g. von Willebrand disease, hemophilia B) - Platelet count < 100 000/mm^3 - Impaired renal function (serum creatinine > 2.0 mg/dL) or active liver disease (alanine aminotransferase/aspartate aminotransferase [ALT/AST] > 5x ULN) - Human immunodeficiency virus (HIV) positive with an absolute CD4 lymphocyte cell count < 250 cells/µL - Known hypersensitivity to the active substance, mouse or hamster protein - Receiving chemotherapy, immune modulatory drugs other than anti-retroviral chemotherapy, or chronic use of oral or intravenous (IV) corticosteroids (> 14 days) within the last 3 months. - Requiring any pre-medication to tolerate FVIII infusions (e.g. antihistamines) - Currently participating in another investigational drug study, or having previously participated in a clinical study involving an investigational drug within 30 days of signing informed consent or participated in completed interventional clinical studies with BAY81-8973 (Kovaltry) - Planned major surgery, defined as surgery with respiratory assistance and/or general anesthesia Part B (PUPs/MTPs): - Any other bleeding disease that is different from hemophilia A (e.g. von Willebrand disease, hemophilia B) - Platelet count < 100 000/mm^3 - Impaired renal function (serum creatinine >2× upper limit of normal [ULN]) or active liver disease (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >5× ULN) based on screening laboratory assessments - MTPs with history of FVIII inhibitor formation - Known hypersensitivity to the active substance, mouse or hamster protein - First treatment with KOVALTRY for high risk bleeding situations (e.g., surgery, intracranial bleed) or requiring intensive or prolonged treatment - Receiving chemotherapy, immune modulatory drugs other than anti-retroviral chemotherapy, or chronic use of oral or intravenous (IV) corticosteroids (> 14 days) within the last 3 months. - Requiring any pre-medication to tolerate FVIII infusions (e.g. antihistamines) - Currently participating in another investigational drug study, or having previously participated in a clinical study involving an investigational drug within 30 days of signing informed consent or participated in completed interventional clinical studies with BAY 81-8973 (Kovaltry) - Planned major surgery, defined as surgery with respiratory assistance and/or general anesthesia - Unable to tolerate volume of blood draws required for study participation

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 1
25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day according to individual requirements for 6 months. The dose decisions are at the discretion of the investigator.
Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 2
12 year-old: 25 to 50 IU of Kovaltry per kg body weight given via intravenous (IV) infusion twice weekly, three times weekly, or every other day for 6 months. >12 year-old: 20 to 40 IU of Kovaltry per kg of body weight given via intravenous (IV) infusion two or three times per week for 6 months. The dose decisions are at the discretion of the investigator.
Recombinant Factor VIII (Kovaltry, BAY81-8973) Treatment Group 3
15 to 50 IU of Kovaltry per kg body weight (minimum dose: 250 IU) given via intravenous (IV) infusions at least once a week. The dose decisions are at the discretion of the investigator.

Locations

Country Name City State
China Beijing Children's Hospital, Capital Medical University Beijing
China Peking Union Medical College Hospital CAMS Beijing
China Chengdu Women & Children's Central Hospital Chengdu Sichuan
China The Children's Hospital Zhengjiang University School of Med. Hangzhou Zhejiang
China Jiangxi Provincial People's Hospital Nanchang Jiangxi
China NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School Nanjing Jiangsu
China Childrens Hospital of Shanghai Shanghai
China Shijiazhuang General Hospital Shijiazhuang Hebei
China 1st Affiliated hospital of Soochow University Suzhou Jiangsu
China Children's Hospital of Shanxi Taiyuan Shanxi

Sponsors (1)

Lead Sponsor Collaborator
Bayer

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Annualized bleeding rate of all bleeding episodes during prophylaxis treatment Annualized bleeding rate (ABR) of all bleeding episodes during prophylaxis treatment in previously treated patients (PTPs). Part A: up to 6 months
Primary Annualized bleeding rate within 48 hours of previous prophylaxis infusion Annualized bleeding rate (ABR) of bleeding episodes within 48 hours of previous prophylaxis infusion in previously untreated/minimally treated patients (PUPs/MTPs). Part B: up to 48 hours post-infusion for at least 50 exposure days
Secondary Annualized bleeding rate of treated bleeding episodes Annualized bleeding rate (ABR) of bleeding episodes treated with BAY81-8973 during prophylaxis treatment. Part A: up to 6 months; Part B: up to at least 50 exposure days
Secondary Annualized bleeding rate of target joint bleeding episodes Annualized bleeding rate (ABR) of target joint bleeding episodes during prophylaxis treatment. Part A: up to 6 months; Part B: up to at least 50 exposure days
Secondary Annualized bleeding rate within 48 hours of previous prophylaxis infusion Annualized bleeding rate (ABR) of bleeding episodes within 48 hours of previous prophylaxis infusion. Part A: up to 48 hours post-infusion for 6 months
Secondary Annualized bleeding rate of all bleeding episodes during prophylaxis treatment Annualized bleeding rate (ABR) of all bleeding episodes during prophylaxis treatment in previously untreated/minimally treated patients (PUPs/MTPs). Part B: up to at least 50 exposure days
Secondary Assessment of response to treatment of bleeds Participants or caregivers assessment to Kovaltry treatment on ISTH 4 point response scale for response to treatment of bleed [excellent, good, moderate or poor]. Part A: up to 6 months; Part B: up to at least 50 exposure days
Secondary Number of surgeries based on physician's assessment of adequacy of hemostasis in minor surgery Physician's assessment of participant's hemostatic response to Kovaltry treatment on the ISTH 4 point response scale for adequacy of hemostasis for surgical procedures [excellent, good, moderate or poor]. Part A: up to 6 months; Part B: up to at least 50 exposure days
Secondary Number of participants without bleeding episodes Number of participants who report no bleeding event during prophylaxis. Part A: up to 6 months; Part B: up to at least 50 exposure days
Secondary Number of infusions per bleeding episode Number of infusions of BAY81-8973 needed to achieve hemostasis for a bleeding episode. Part A: up to 6 months; Part B: up to at least 50 exposure days
Secondary Factor VIII usage BAY81-8973 consumption during the study. Part A: up to 6 months; Part B: up to at least 50 exposure days
Secondary Factor VIII inhibitor development by the Nijmegen Bethesda assay Number of participants with positive Factor VIII (FVIII) inhibitor test (=0.6 Bethesda unit [BU]). Part A: up to 6 months; Part B: up to at least 50 exposure days
Secondary In-vivo recovery In-vivo recovery (or incremental recovery) is defined as the increase in the circulating FVIII activity level for one unit (IU) of the FVIII product per kilogram body weight. Part A: baseline, Month 2 and Month 6; Part B: baseline and end of study
Secondary Maximum concentration (Cmax) of Kovaltry in plasma Cmax: Maximum observed drug concentration following an infusion of 50 IU/kg. Part A: pre-infusion and up to 30 minutes post-infusion
Secondary Area under the plasma concentration versus time curve (AUC) from zero to infinity after single (first) dose AUC: The total area under the plasma concentration versus time curve following an infusion of 50 IU/kg. Part A: pre-infusion and up to 48 hours post-infusion
Secondary Half-life (t1/2) of Kovaltry in plasma t1/2: Terminal half-life is the time the plasma concentration during terminal phase is halved following an infusion of 50 IU/kg. Part A: pre-infusion and up to 48 hours post-infusion
Secondary Treatment-emergent adverse events Part A: up to 6 months; Part B: up to at least 50 exposure days
See also
  Status Clinical Trial Phase
Completed NCT03834727 - Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
Completed NCT03191799 - A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Phase 3
Completed NCT01599819 - BAX 855 Dose-Escalation Safety Study Phase 1
Terminated NCT04541628 - Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A Phase 1/Phase 2
Completed NCT02847637 - A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors Phase 3
Completed NCT04072237 - Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia Phase 1
Completed NCT04085458 - Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophilia A (Post-marketing Investigation) Phase 4
Recruiting NCT05987449 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A Phase 1/Phase 2
Active, not recruiting NCT04621916 - Preventing Inhibitor Recurrence Indefinitely Phase 4
Not yet recruiting NCT02888223 - Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A Phase 1
Completed NCT02528968 - National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A N/A
Completed NCT02225483 - Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function N/A
Completed NCT02199717 - An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia N/A
Completed NCT01217255 - Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
Terminated NCT00995046 - Individually Tailored Prophylaxis in Patients With Severe Hemophilia A N/A
Completed NCT00969319 - Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America N/A
Completed NCT00868530 - Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects Phase 3
Completed NCT00839202 - Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay N/A
Completed NCT00629837 - Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980 Phase 1
Completed NCT02093741 - ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)